Relapsing #malaria can cause repeated episodes of illness from a single mosquito bite. A new study from Papua New Guinea & Indonesia is helping build the evidence needed to introduce improved approaches into routine care. More: bit.ly/4fwLLOV

The cost of responding to antimalarial drug resistance in Africa will only grow as resistance spreads. Beyond new #malaria medicines, investment must also target surveillance, health systems and local manufacturing. More: bit.ly/4pP8Ilm

When Will Malaria Meds Stop Working In Africa?

“The continent should take the matter of resistance very, very seriously...Resistance should be seen as an emergency situation.”

bit.ly

Congrats to MMV's André-Marie Tchouatieu, who was recognized for his visionary leadership in the fight against #malaria at Benin's La Nuit du Paludisme. The Exceptional Commitment Award celebrates his success in mobilizing minds, inspiring generations and saving countless lives.

Between 2019 and 2024, Ghana reduced #malaria deaths among children under 5 by 86%. Its experience shows the value of layering interventions and ensuring vaccines, bed nets, diagnosis, treatment and community-centred delivery work together. Read more: bit.ly/4fRxcH6

How Ghana Slashed Child Malaria Deaths By 86% - Health Policy Watch

For decades, malaria has been one of Africa's most persistent health challenges. In Ghana, it was once the leading cause of death for children under five. Bed

bit.ly

MMV met with leaders from the Japan Institute for Health Security (JIHS) to discuss Japan's approach to #malaria and health security, showcase MMV's pipeline of innovative malaria medicines and explore opportunities for future collaboration.

Long-acting injectables could provide protection from malaria for up to 6 months with a single administration. Cristina Donini explains how it works. Reaching zero #malaria requires continued #innovation & sustained commitment to get breakthroughs to those who need them most.

Spotlight on Japan: today, partners from around the world convened in Tokyo for the Japan symposium on #malaria R&D. Discussions focused on the partnerships, science & innovation advancing next-generation malaria prevention & treatment tools. More: bit.ly/4pucJLR

Japan convenes global leaders in malaria research and development to strengthen partnerships for innovative prevention and treatment tools | Medicines for Malaria Venture

bit.ly

From discovery to delivery, collaboration across the global malaria community underpins innovation and progress. Here are three ways Japan contributes to the fight against one of the world's deadliest diseases.

#PressRelease A potential new antimalarial has shown promising results in its first study in humans. The investigational non-artemisinin medicine rapidly killed #malaria parasites and was generally well tolerated in infected volunteers. Read more: bit.ly/3T5KJ4Y

New malaria drug candidate shows early promise in human study | Medicines for Malaria Venture

bit.ly

A single-dose cure for #malaria: one patient, one visit, one treatment, done. MMV’s Cristina Donini explains how it works. Reaching zero malaria requires continued #innovation and the sustained commitment to get the latest breakthroughs to the people who need them most.

Last week, representatives from the MMV/DNDi joint regulatory sciences platform and medical affairs met with the Ghana FDA at the Ghanaian Mission in Geneva to discuss how we can reinforce our shared commitment to closer regulatory collaboration.

MMV convened experts in clinical trials, immunology, modelling  & machine learning to define the data needed to build AI-powered models of the immune response to #malaria. Learn more about 3 of our latest AI drug discovery and development partnerships: bit.ly/4yalrCN

MMV and @deepmirror.bsky.social are advancing the next phase of Drug Design for Global Health (dd4gh), our open-access AI-powered drug discovery platform, with a new grant from the @gatesfoundation.bsky.social. Learn more: bit.ly/4beUFze

MMV and deepmirror continue partnership to advance AI tool for global health drug discovery | Medicines for Malaria Venture

bit.ly

Have you heard about the new collaboration between MMV, @dndi.org and @gardp.bsky.social? This strategic agreement responds to a growing reality: global health challenges are too complex for any one organization to solve alone. See how collaboration can maximize impact: bit.ly/3SHIzIo

‘It’s possible to have a collective success’: three Geneva health non-profits bolster ties amid shrinking aid - Geneva Solutions

Three Geneva-based health organisations will join forces to speed up research and development into treatments for malaria, neglected diseases and drug-resistant infections, amid global aid cuts and ca...

bit.ly

From single-dose cures to long-acting injectables, next-gen #malaria tools could transform how the disease is prevented & treated. Today, MMV's Cristina Donini features in the Daily Express, photographed by Rankin for @malarianomoreuk.bsky.social's #FacesOfInnovation campaign: bit.ly/4woWi5v

EU ability to prevent, detect and respond to infectious diseases relies on global collaboration and thriving #innovation. In this joint paper with PDP partners, we highlight @globalhealthedctp3.bsky.social's role in Europe–Africa research, clinical development and access: bit.ly/4xKn21U

LAIs are a new frontier in global health. Realizing their potential requires sustained investment and collaboration. MMV's Cristina Donini joined leaders from Gilead Sciences and Johnson & Johnson to discuss how lessons from HIV can advance LAIs for TB and #malaria. bit.ly/3QrqdLj

Long-Acting Injectables: The New Frontier in Global Health

Long-Acting Injectables: The New Frontier in Global Health - Grand Challenges Annual Meeting 2026

bit.ly

We are deeply saddened by the passing of Prof. Bob Sinden, a dear friend, collaborator and internationally recognized leader in cellular parasitology. We extend our heartfelt condolences to his family, friends and colleagues. Read our tribute: bit.ly/4gASCci

Remembering Professor Robert Sinden, a pioneer in malaria transmission biology | Medicines for Malaria Venture

bit.ly

We cannot meet today’s health needs with yesterday’s tools. Improving coordination & delivery while neglecting #innovation risks creating a system that is better organized but not more effective. Leaders from MMV, @dndi.org & @gardp.bsky.social explain why: bit.ly/4oyhtzo

Opinion: Global health reform must bolster Innovation | Medicines for Malaria Venture

bit.ly

MMV and @dndi.org have launched the first joint regulatory sciences platform between PDPs! By bringing together regulatory expertise, we can: → Pool knowledge and speak with one voice → Define evidence standards for future medicines → Strengthen impact Read more: bit.ly/4a4OEEP

MMV and DNDi pool regulatory expertise to accelerate access to lifesaving medicines | Medicines for Malaria Venture

bit.ly

A new version of #MMVSola is now live 🔹 Dose prediction tools for LAIs 🔹 Enhanced interactive plots & tables 🔹 Improved models to better estimate drug properties 🔹 Built-in documentation & user guides Try it for free here: mmvsola.org

The antimalarial toolbox we have today was built through partnership. The next generation of interventions will be too. PDPs like MMV bring together the expertise needed to turn scientific discovery into new tools. See why the PDP model matters: bit.ly/4xbMPQq

Medicines for Malaria Venture : Ending Malaria, Rewriting the Future | Healthcare Outlook

Medicines for Malaria Venture is continuing to innovate its R&D pipeline, collaborate with stakeholders, and refine its product development partnership model. Dr Martin Fitchet, CEO, tells us more.

bit.ly

To accelerate #malaria elimination, next-gen antimalarials must be developed with simplicity in mind. LAIs could provide lasting protection from a single intervention. MMV & partners recently explored how this innovation can support high-burden settings: bit.ly/4wSkvCB

MMV hosts workshop to advance long‑acting injectables for high‑burden diseases | Medicines for Malaria Venture

bit.ly

"The science has never looked so good or so promising." The challenge is turning scientific progress into medicines that reach the people who need them. Watch MMV's Emma Hannay on the importance of collaboration between @dndi.org, @gardp.bsky.social and MMV.

Drugs for Neglected Diseases initiative (DNDi)@dndi.org · 2mo ago

We join forces with @gardp.bsky.social & @mmv.org to accelerate drug development for patients in greatest need! Emma Hannay, Chief Strategy Officer at MMV, explains why this collaboration is especially important in this changing global health ecosystem. 👉Press Release: dndi.org/press-releas...

#PressRelease @dndi.org, @gardp.bsky.social and MMV are joining forces to strengthen collaboration, maximize the impact of global health R&D, and accelerate the development of life-saving treatments. Read the press release: bit.ly/4fo8xu0

DNDi, GARDP, and MMV join forces to accelerate drug development for patients in greatest need | Medicines for Malaria Venture

bit.ly

MMV’s Project of the Year 2025 is a powerful example of how we can go farther and faster by working together. This week, we convened the partners behind Coartem® Baby, the first #malaria treatment specifically designed for newborns and young infants: bit.ly/4en79Xw

Another milestone in the treatment of vivax #malaria. Thailand is the second country to approve paediatric tafenoquine, a single-dose treatment designed to help prevent relapse. Co-developed by MMV and GSK, pTQ can help children recover without the threat of repeated relapse.

MMV’s 9th African call for proposals is now open! We’re looking for projects that could help accelerate #malaria drug discovery, from assay development and AI-supported discovery to innovative biology and novel antimalarials. Apply by 29 August: bit.ly/3Rt1h6j

As #malaria becomes more complex, we need simpler tools. #Innovations like single-dose cures & long-acting injectables can accelerate elimination in complex settings. Because the best innovations are the ones people actually use. That’s what makes them elimination accelerators.

What does it take to move new health technologies from pilot projects into routine care? Last month in Thailand, MMV colleagues joined NMPs from across the Asia-Pacific to observe the implementation of tools for relapsing #malaria in real-world settings & exchange insights.